Lincoln Pharmaceuticals (531633) Q4 05/06 earnings summary

Executive summary

• FY2005-06 sales rose 49% to ₹5,647.69 lakh; profit after tax increased to ₹245.14 lakh from ₹152.94 lakh.

• Growth coincided with higher selling and administrative expenses, which reached ₹1,018.78 lakh versus ₹212.61 lakh in FY2004-05.

Financial highlights

• Sales revenue was ₹5,647.69 lakh; total income including other income and stock variation was ₹5,957.98 lakh, versus ₹3,879.97 lakh in FY2004-05.

• Profit before tax was ₹330.81 lakh, up from ₹206.18 lakh; profit after tax was ₹245.14 lakh, versus ₹152.94 lakh.

• Materials consumption was ₹2,142.67 lakh versus ₹2,167.95 lakh; personnel expenses increased to ₹387.52 lakh from ₹221.70 lakh.

• Financial charges rose to ₹105.81 lakh from ₹62.49 lakh; depreciation was ₹51.94 lakh versus ₹49.58 lakh.

Outlook and guidance

• FY2006-07 outlook was cautiously optimistic, with plans to build market share through new products, wider geographic coverage, and larger job-work contracts.

• Brand building, added products, and job work for multinational companies were identified as growth priorities.